Uproleselan sodium by GlycoMimetics for Multiple Myeloma (Kahler Disease): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Uproleselan sodium overview

Uproleselan sodium (GMI-1271) is under the development for the treatment of acute myeloid leukemia (AML), coronavirus disease 2019 (COVID-19) pneumonia, myelodysplastic syndrome, chronic myelogenous leukemia and Inflammatory diseases. The drug candidate is administered through intravenous route. It acts by targeting E-selectin. GMI-1271 is a mimetic of naturally occurring carbohydrate (glycomimetics). It was also under development for deep venous thrombosis, pancreatic cancer, multiple myeloma and breast cancer.

GlycoMimetics overview

GlycoMimetics is a clinical-stage biotechnology company that discovers and develops small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s lead pipeline product, uproleselan, is being developed for the treatment of relapsed/refractory acute myeloid leukemia (AML) in adults. GlycoMimetics designs galectin inhibitors for advancing treatment options for various diseases. The company designs and tests viral and bacterial entry inhibitors for dendritic cell receptors. The company uses proprietary glycobiology technology to develop treatments for diseases. It also offers clinical research programs. GlycoMimetics is headquartered in Rockville, Maryland, the US.

For a complete picture of Uproleselan sodium’s drug-specific PTSR and LoA scores, buy the report here.